Phase 3 study of pembrolizumab with concurrent chemoradiation therapy followed by pembrolizumab with or without olaparib vs. concurrent chemoradiation therapy in patients with newly diagnosed limited-stage small-cell lung cancer: KEYLYNK-013 Meeting Abstract
| Authors: | Rimner, A.; Lai, V.; Califano, R.; Jabbour, S. K.; Faivre-Finn, C.; Cho, B. C.; Kato, T.; Yu, J.; Yu, L.; Zhao, B.; Pietanza, M. C.; Byers, L. |
| Abstract Title: | Phase 3 study of pembrolizumab with concurrent chemoradiation therapy followed by pembrolizumab with or without olaparib vs. concurrent chemoradiation therapy in patients with newly diagnosed limited-stage small-cell lung cancer: KEYLYNK-013 |
| Meeting Title: | 63rd Annual Meeting of the American Society for Radiation Oncology (ASTRO 2021) |
| Journal Title: | International Journal of Radiation Oncology, Biology, Physics |
| Volume: | 111 |
| Issue: | 3 Suppl. |
| Meeting Dates: | 2021 Oct 24-27 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0360-3016 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2021-11-01 |
| Start Page: | e468 |
| End Page: | e469 |
| Language: | English |
| ACCESSION: | WOS:000715803800966 |
| PROVIDER: | wos |
| DOI: | 10.1016/j.ijrobp.2021.07.1308 |
| Notes: | Meeting Abstract: 2971 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work